N,N′-diphenylpyridine-2,5-dicarboxamide | 313557-37-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N′-diphenylpyridine-2,5-dicarboxamide
• 英文别名: N,N'-diphenyl-2,5-pyridinedicarboxamide；2-N,5-N-diphenylpyridine-2,5-dicarboxamide
• CAS: 313557-37-8
• 化学式: C₁₉H₁₅N₃O₂
• mdl: MFCD00805949
• 分子量: 317.347
• InChiKey: OLFSCPKAHMFATL-UHFFFAOYSA-N

物化性质

• 沸点：
  397.4±27.0 °C(Predicted)
• 密度：
  1.320±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  pyridine-2,5-dicarboxylic acid dichloride 、 苯胺 以 甲苯 为溶剂， 反应 0.17h， 生成 N,N′-diphenylpyridine-2,5-dicarboxamide
  参考文献：
  名称：

  Probing the intermolecular interactions of aromatic amides containing N-heterocycles and triptycene

  摘要：

  合成并研究了一系列掺入N-杂环或三蝶烯单元的芳香酰胺，以探讨此类化学修饰对分子间相互作用的影响。获得了多种杂环酰胺和含三蝶烯的酰胺的单晶。比较了相关分子的晶体结构、氢键、晶格能、溶解度和熔点。杂环中适当位置的氮原子被发现与酰胺 NH 形成分子内氢键，但代价是削弱或破坏分子间氢键。尽管如此，氢键变化对溶解度和熔点的影响仍然有限。独特的是，三蝶烯单元有效地提高了酰胺的溶解度，而不会降低分子的耐热性。

  DOI：

  10.1039/c4ce00089g

文献信息

• Palladium-catalysed aminocarbonylation of diiodopyridines
  作者：Attila Takács、Georgina Márta Varga、Johanna Kardos、László Kollár

  DOI：10.1016/j.tet.2017.02.062

  日期：2017.4

  The aminocarbonylation of 2,5- and 2,3-diiodopyridine, as well as 2-chloro-3,4-diiodopyridine with carbon monoxide and various primary and secondary amines was carried out using palladium-catalysed aminocarbonylation. The formation of the products containing carboxamide and ketocarboxamide functionalities was accompanied by the formation of imides when ortho-diiodo compounds were used as substrates

  2，5-和2，3-二碘吡啶以及2-氯-3，4-二碘吡啶与一氧化碳以及各种伯胺和仲胺的氨基羰基化反应是通过钯催化的氨基羰基化反应进行的。当使用邻二碘代化合物作为底物时，形成含有羧酰胺和酮羧酰胺官能团的产物伴随着酰亚胺的形成。尽管有几种可能的反应途径，但通过适当地改变反应条件，大多数产物被合成为主要产物，具有合成目的的产率。
• Aromatic 1,4-DI-Carboxylamides and their use
  申请人：The Genetics Company, Inc.

  公开号：EP1932834A1

  公开（公告）日：2008-06-18

  The invention relates to novel compounds of formula I Wherein X, Y, Z represent independently from one another C or N, n stands for 1, 2, 3, m is 0 or 1, p stands for 0 or an integer from 1 to 6, R1, R2 represent independently from one another hydrogen, a halogen atom, a hydroxyl group, a C1-C3 alkyl group and a C1-C3 alkoxy group, R3 represents, independently from one another if p is not 0, hydrogen, halogen, a C1-C5 linear or branched alkyl, a carboxylyl, a carbomethoxyl, carboethoxyl, a benzyl, an acyl, a hydroxyl, a C1-C4 linear or branched alkoxyl, a trifluoromethyl, a cyano, a morpholino, a 1,3-dioxolyl, an N-acetylamidyl or an amidoyl group, a saturated 5-8 membered ring, a heterocyclic ring, optionally substituted by a C1-C3 alkyl, a hydroxyl or a benzyl group, a C1-C6 alkylsulfonyl, a mono or disubstituted C1-C5 alkyl group, a branched or a cyclic amine, R6 is H or part of a alicyclic,heteroalicyclic ring system, if m is 0 then C represents CF3 or a branched or unbranched C1-C4 alkyl group, if m = 1 then C represents -CH2-O-, -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2(CH2)CH2- or denotes a chemical bond between N-C or C-C, the CONR6 group may be linked to C either via its carbon or via its nitrogen atom, CYC stands for a by R3 substituted or unsubstituted phenyl, pyridinyl, naphthyl, quinolinyl, isoquinolinyl, isoxaxolinyl, thiophenyl, 1,3,4-thiadiazazolidinyl, furanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, morpholinyl, furanyl, cyclohexenyl, and chromen-2-on-yl and its use as a medicament for the treatment of cancer.

  本发明涉及式 I 的新型化合物 其中，X、Y、Z 相互独立地代表 C 或 N，n 代表 1、2、3，m 为 0 或 1，p 代表 0 或 1 至 6 的整数，R1、R2 相互独立地代表氢、卤素原子、羟基、C1-C3 烷基和 C1-C3 烷氧基，R3 相互独立地代表（如果 p 不为 0）氢、卤素原子、C1-C5 直链或支链烷基、羧基、羰基、羧氧羰基、苄基、酰基、C1-C5直链或支链烷基、羧基、甲氧羰基、甲氧羰基、苄基、酰基、羟基、C1-C4直链或支链烷氧基、三氟甲基、氰基、吗啉基、1、3-二氧戊基、N-乙酰氨基或酰胺酰基、饱和的 5-8 位环、杂环（可选择被 C1-C3 烷基、羟基或苄基取代）、C1-C6 烷基磺酰基、C1-C4 直链或支链烷氧基、三氟甲基、氰基、吗啉基、1, 3-二氧戊基、N-乙酰氨基或酰胺酰基R6 是 H 或脂环、杂脂环系统的一部分，如果 m 为 0，则 C 代表 CF3 或支链或未支链的 C1-C4 烷基，如果 m = 1，则 C 代表 -CH2-O-、- -、- -、- -、- ( ) - 或表示 N-C 或 C-C 之间的化学键、CONR6 基团可以通过碳原子或氮原子与 C 相连，CYC 表示由 R3 取代或未取代的苯基、吡啶基、萘基、喹啉基、异喹啉基、异噁唑啉基、噻吩基、1,3,4-噻二唑烷基、呋喃基、四氢喹啉基、四氢异喹啉基、吗啉基、呋喃基、环己烯基和 2-烯铬基，并用作治疗癌症的药物。
• AROMATIC 1,4-DI-CARBOXYLAMIDES AND THEIR USE
  申请人：Garcia Gabriel

  公开号：US20100204219A1

  公开（公告）日：2010-08-12

  The invention relates to novel compounds of formula (I) wherein X, Y, Z represent independently from one another C or N, n stands for 1, 2, 3, m is 0 or 1, p stands for 0 or an integer from 1 to 6, R 1 , R 2 represent independently from one another hydrogen, a halogen atom, a hydroxyl group, a C 1 -C 3 alkyl group and a C 1 -C 3 alkoxy group, R 3 represents, independently from one another if p is not 0, hydrogen, halogen, a C 1 -C 5 linear or branched alkyl, a carboxylyl, a carbomethoxyl, carboethoxyl, a benzyl, an acyl, a hydroxyl, a C 1 -C 4 linear or branched alkoxyl, a trifluoromethyl, a cyano, a morpholino, a 1,3-dioxolyl, an N-acetylamidyl or an amidoyl group, a saturated 5-8 membered ring, a heterocyclic ring, optionally substituted by a C 1 -C 3 alkyl, a hydroxyl or a benzyl group, a C 1 -C 6 alkylsulfonyl, a mono or disubstituted C 1 -C 5 alkyl group, a branched or a cyclic amine, R 6 is H or part of a alicyclic, heteroalicyclic ring system, if m is 0 then C represents CF 3 or a branched or unbranched C 1 -C 4 alkyl group, if m=1 then C represents —CH 2 —O—, —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, —CH 2 (CH 2 )CH 2 — or denotes a chemical bond between N—C or C—C, the CONR 6 group may be linked to C either via its carbon or via its nitrogen atom, CYC stands for a by R 3 substituted or unsubstituted phenyl, pyridinyl, naphthyl, quinolinyl, isoquinolinyl, isoxaxolinyl, thiophenyl, 1,3,4 -thiadiazazolidinyl, furanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, morpholinyl, furanyl, cyclohexenyl, and chromen-2-on-yl and its use as a medicament for the treatment of cancer.